Recent decisions against AbbVie Inc.'s Humira patents highlight the continued threat of the inter partes review process to biopharma patents. But the proceeding itself could be imperiled now that the US Supreme Court has agreed to hear a case challenging its constitutionality.
On June 9, the US Patent and Trademark Office's Patent Trial and Appeal Board issued a pair of final written...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?